Physician profile
Waseem Barham
NPI 1053540203
$13,479.03
in general payments reported to CMS, 2019-2025
25 companies · $2,191 in 2025
The $2,191 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $470 · 2021: $355 · 2022: $414 · 2023: $5,951 · 2024: $3,092 · 2025: $2,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,893 · Food and Beverage: $4,201 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,893.28 |
| Food and Beverage | $4,201.09 |
| Education | $138.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,676.85 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $3,478.68 | 2019-2025 | Angiojet Ultra 5000a, Jetstream Sc, Avvigo Guidance System |
| Abbott Laboratories | $1,094.57 | 2023-2025 | Triclip, Accent |
| Abiomed | $980.72 | 2020-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $795.59 | 2019-2025 | |
| Philips North America LLC | $753.03 | 2023-2025 | IV Other |
| Shockwave Medical, INC | $523.73 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $303.20 | 2022-2025 | Symplicity G3 |
| E.R. Squibb & Sons, L.L.C. | $217.68 | 2019-2023 | Camzyos |
| Janssen Pharmaceuticals, INC | $213.38 | 2019-2024 | Xarelto |
| Amgen INC. | $186.16 | 2022-2024 | Repatha |
| Actelion Pharmaceuticals US, INC. | $155.13 | 2023 | Opsumit, Uptravi |
| Bard Peripheral Vascular, INC. | $136.73 | 2023 | |
| Cardiovascular Systems INC. | $120.33 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $119.70 | 2021-2023 | Brilinta, Farxiga |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $112.01 | 2019 | |
| Pfizer INC. | $106.10 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $102.18 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.82 | 2021-2024 | Jardiance |
| Penumbra, INC. | $91.75 | 2024 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $60.89 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $49.12 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.76 | 2020-2025 | Lifevest |
| Lilly USA, LLC | $44.46 | 2025 | Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals, LTD. | $17.46 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waseem Barham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.